Rituxan
FDA Approves Riabni, Third Biosimilar to Rituxan
The FDA Approved Amgen's Riabni, the 3rd biosimilar to the originator, U.S.-licensed Rituxan.
DECEMBER 18, 2020
FDA Approves Truxima, First Biosimilar to Rituxan
Truxima can be used to treat three types of adults with non-Hodgkin lymphoma.
NOVEMBER 29, 2018
Rituxan Hycela Approved for FL, DLBCL, CLL
Rituximab and hyaluronidase human (Rituxan Hycela, Genentech) was approved for subcutaneous injection for the ...
JUNE 23, 2017
$19.6 Million from PCORI Supports MS Research
Funding covers four major new studies assessing the comparative effectiveness of several MS therapies.
JULY 25, 2016
Stem Cell Rx for MS Stirs Debate
Is stem cell therapy for MS a breakthrough or "radical and potentially dangerous?"
FEBRUARY 2, 2016
